Your browser doesn't support javascript.
loading
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors.
Hornak, Tomas; Mayer, Jiri; Cicatkova, Petra; Semerad, Lukas; Kvetkova, Anezka; Klamova, Hana; Faber, Edgar; Belohlavkova, Petra; Karas, Michal; Stejskal, Lukas; Cmunt, Eduard; Cerna, Olga; Srbova, Dana; Zizkova, Hana; Vrablova, Lucia; Skoumalova, Ivana; Voglova, Jaroslava; Jurkova, Tereza; Chrapava, Marika; Jurcek, Tomas; Jeziskova, Ivana; Jarosova, Marie; Machova Polakova, Katerina; Papajik, Tomas; Zak, Pavel; Jindra, Pavel; Zackova, Daniela.
Afiliação
  • Hornak T; Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.
  • Mayer J; Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.
  • Cicatkova P; Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
  • Semerad L; Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.
  • Kvetkova A; Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.
  • Klamova H; Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.
  • Faber E; Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
  • Belohlavkova P; Dpt. of Hemato-oncology, University Hospital Olomouc and Palacky University, Olomouc, Czech Republic.
  • Karas M; 4th Dpt. of Internal Medicine and Hematology, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic.
  • Stejskal L; Dpt. of Hemato-oncology, University Hospital Pilsen and Charles University, Pilsen, Czech Republic.
  • Cmunt E; Dpt. of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic.
  • Cerna O; Dpt. of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
  • Srbova D; 1st. Internal Dpt, General University Hospital Prague, Prague, Czech Republic.
  • Zizkova H; Dpt. of Hematology, University Hospital Kralovske Vinohrady and Charles University, Prague, Czech Republic.
  • Vrablova L; Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
  • Skoumalova I; Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
  • Voglova J; Dpt. of Hemato-oncology, University Hospital Olomouc and Palacky University, Olomouc, Czech Republic.
  • Jurkova T; Dpt. of Hemato-oncology, University Hospital Olomouc and Palacky University, Olomouc, Czech Republic.
  • Chrapava M; 4th Dpt. of Internal Medicine and Hematology, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic.
  • Jurcek T; Institute of Biostatistics and Analyses, Brno, Czech Republic.
  • Jeziskova I; Institute of Biostatistics and Analyses, Brno, Czech Republic.
  • Jarosova M; Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.
  • Machova Polakova K; Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.
  • Papajik T; Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.
  • Zak P; Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
  • Jindra P; Dpt. of Hemato-oncology, University Hospital Olomouc and Palacky University, Olomouc, Czech Republic.
  • Zackova D; 4th Dpt. of Internal Medicine and Hematology, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic.
Am J Hematol ; 99(4): 763-766, 2024 Apr.
Article em En | MEDLINE | ID: mdl-38317312
ABSTRACT
Overall survival of patients classified according to the European LeukemiaNet 2020 classification. Chronic phase (CP), accelerated phase (AP), blast crisis (BC), low risk (LR), intermediate risk (IR), high risk (HR).
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva Limite: Humans Idioma: En Revista: Am J Hematol Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva Limite: Humans Idioma: En Revista: Am J Hematol Ano de publicação: 2024 Tipo de documento: Article